Setyawan, Y. “Nilotinib As the First Line Therapy in Managing Chronic Myelogenous Leukemia”. E-CliniC, vol. 9, no. 2, Mar. 2021, pp. 342-50, doi:10.35790/ecl.v9i2.32699.